10,650 Shares in Labcorp Holdings Inc. $LH Purchased by Accredited Investors Inc.

Accredited Investors Inc. bought a new position in Labcorp Holdings Inc. (NYSE:LH) in the first quarter, HoldingsChannel reports. The fund bought 10,650 shares of the medical research company’s stock, valued at approximately $2,842,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Labcorp during the fourth quarter worth approximately $26,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Labcorp in the fourth quarter valued at approximately $27,000. JPL Wealth Management LLC bought a new position in Labcorp in the third quarter worth approximately $28,000. Eagle Bay Advisors LLC purchased a new position in Labcorp during the 4th quarter worth $29,000. Finally, DV Equities LLC purchased a new position in Labcorp during the 4th quarter worth $29,000. Institutional investors own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LH shares. Wall Street Zen downgraded Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Robert W. Baird set a $334.00 price objective on shares of Labcorp in a research note on Friday, May 1st. Finally, Evercore reissued an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Labcorp currently has an average rating of “Moderate Buy” and an average price target of $313.33.

Labcorp Price Performance

LH opened at $277.51 on Friday. The firm has a market capitalization of $22.76 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 1.94 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. The business’s 50-day moving average is $263.69 and its two-hundred day moving average is $267.01. Labcorp Holdings Inc. has a 1 year low of $241.81 and a 1 year high of $293.72.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The firm had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Research analysts anticipate that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Insider Buying and Selling at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer owned 107,234 shares of the company’s stock, valued at approximately $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 92 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $26,329.48. Following the transaction, the executive vice president owned 3,904 shares in the company, valued at approximately $1,117,285.76. This trade represents a 2.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 6,991 shares of company stock worth $1,796,696. 0.84% of the stock is owned by insiders.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.